如今，肝癌是最令人不安的癌症类型之一，可影响任何性别。掺入布洛芬 (IBU) 和柚皮素 (NAR) 的玉米醇溶蛋白/酪蛋白酸钠纳米颗粒 (NP) 具有更高的生物利用度和高包封率 (EE%)。这些纳米粒子是均匀的球形。在体外，对用于研究人类肝癌的 HepG2 细胞系的细胞毒性分析表明，封装药物（NAR 和 IBU 分别为 86.49% ± 1.90 和 78.52% ± 1.98）的 IC50 值显着低于单个药物或他们的组合自由形式。此外，IBU和NAR的组合指数分别为0.623和0.155，表明两者具有联合有益作用。划痕伤口愈合测定结果还表明，游离药物和工程纳米粒子比未处理的细胞具有更显着的抗迁移作用。根据体外结果，设计的纳米颗粒还可以减少血管生成和增殖，同时诱导细胞凋亡。总之，治疗肝癌的新方法可能在于将多种药物纳米封装在纳米颗粒中。

Nowadays, liver cancer is one of the most disturbing types of cancer that can affect either sex. Nanoparticles (NPs) of zein/sodium caseinate incorporating ibuprofen (IBU) and naringenin (NAR) have improved bioavailability and a high encapsulation efficiency (EE%). These nanoparticles are uniformly spherical. In vitro, cytotoxicity analysis on HepG2 cell lines, which are used to study human liver cancer, shows that encapsulated drugs (86.49% ± 1.90, and 78.52% ± 1.98 for NAR and IBU, respectively) have significantly lower IC50 values than individual drugs or their combined free form. In addition, the combination indices of 0.623 and 0.155 for IBU and NAR, respectively, show that the two have joint beneficial effects. The scratch wound healing assay results also show that the free drugs and the engineered NPs have a more significant anti-migratory effect than the untreated cells. The designed nanoparticles also reduce angiogenesis and proliferation while inducing apoptosis, according to in vitro results. In conclusion, a new approach to treating liver cancer may lie in the nanoencapsulation of numerous drugs within nanoparticles.